Clinical Trial Detail

NCT ID NCT02604511
Title Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

lymphoplasmacytic lymphoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.